These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37061828)

  • 1. Evidence and Uncertainties Surrounding Renin-Guided Medical Therapy for Primary Aldosteronism.
    Hiremath S; Hundemer GL
    Am J Hypertens; 2023 Jul; 36(8):428-430. PubMed ID: 37061828
    [No Abstract]   [Full Text] [Related]  

  • 2. Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism.
    Pecori A; Buffolo F; Burrello J; Mengozzi G; Rumbolo F; Avataneo V; D'Avolio A; Rabbia F; Bertello C; Veglio F; Mulatero P; Monticone S
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3655-e3664. PubMed ID: 33942084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary aldosteronism: considerations about the evaluation of the aldosterone to renin ratio during canrenone treatment.
    Armanini D; Sabbadin C; Boscaro M
    J Endocrinol Invest; 2021 Sep; 44(9):2009-2010. PubMed ID: 33454931
    [No Abstract]   [Full Text] [Related]  

  • 4. Are there unknown mineralocorticoids in low-renin essential hypertension?
    Hollifield JW; Slaton PE; Wilson HM; Sennett JA; Yarbro L; Island DP; Liddle GW
    Mayo Clin Proc; 1977 May; 52(5):329-33. PubMed ID: 323587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism.
    Tezuka Y; Turcu AF
    Endocr Pract; 2020 Dec; 26(12):1416-1424. PubMed ID: 33471733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent progress in the diagnosis and treatment of primary aldosteronism.
    Yoshida Y; Shibata H
    Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.
    Seifarth C; Trenkel S; Schobel H; Hahn EG; Hensen J
    Clin Endocrinol (Oxf); 2002 Oct; 57(4):457-65. PubMed ID: 12354127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some considerations about evolution of idiopathic primary aldosteronism.
    Armanini D; Fiore C
    J Endocrinol Invest; 2009 Jul; 32(7):623-5. PubMed ID: 19893360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant Hypertension and Bilateral Primary Aldosteronism.
    Murai S; Kakeshita K; Imamura T; Koike T; Fujioka H; Yamazaki H; Kinugawa K
    Intern Med; 2023 Sep; 62(18):2675-2680. PubMed ID: 36725041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine and hypertensive disorders of potassium regulation: primary aldosteronism.
    Weiner ID
    Semin Nephrol; 2013 May; 33(3):265-76. PubMed ID: 23953804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of aldosterone and blood pressure with the risk for cardiovascular events after treatments in primary aldosteronism.
    Haze T; Hirawa N; Yano Y; Tamura K; Kurihara I; Kobayashi H; Tsuiki M; Ichijo T; Wada N; Katabami T; Yamamoto K; Oki K; Inagaki N; Okamura S; Kai T; Izawa S; Yamada M; Chiba Y; Tanabe A; Naruse M
    Atherosclerosis; 2021 May; 324():84-90. PubMed ID: 33831673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights into the medical management of primary aldosteronism.
    Hsueh WA
    Hypertension; 1986 Jan; 8(1):76-82. PubMed ID: 3510974
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rectal electrical potential difference and plasma aldosterone in hyperaldosteronism and low-, normal- and high-renin hypertension].
    Skrabal F; Mauser R
    Wien Klin Wochenschr; 1976 Dec; 88(23):777-81. PubMed ID: 1014711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Normoaldosterone spironolactone sensitive hypertension--a case report].
    Krysiak R; Okopień B; Herman ZS
    Pol Arch Med Wewn; 2005 Oct; 114(4):978-81. PubMed ID: 16789524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using Renin Activity to Guide Mineralocorticoid Receptor Antagonist Therapy in Patients with Low Renin and Hypertension.
    Mansur A; Vaidya A; Turchin A
    Am J Hypertens; 2023 Jul; 36(8):455-461. PubMed ID: 37013957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary aldosteronism: are we missing the wood for the trees?
    Funder JW
    Horm Metab Res; 2012 Mar; 44(3):251-3. PubMed ID: 22281545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary aldosteronism: diagnostic and treatment strategies.
    Mattsson C; Young WF
    Nat Clin Pract Nephrol; 2006 Apr; 2(4):198-208; quiz, 1 p following 230. PubMed ID: 16932426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineralocorticoid antagonism and cardiac hypertrophy.
    Nagata K
    Curr Hypertens Rep; 2008 Jun; 10(3):216-21. PubMed ID: 18765093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is primary aldosteronism underdiagnosed in clinical practice?
    Fiquet-Kempf B; Launay-Mignot P; Bobrie G; Plouin PF
    Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1083-6. PubMed ID: 11903321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.